Equities

Niox Group PLC

Niox Group PLC

Actions
  • Price (EUR)0.72
  • Today's Change0.01 / 1.41%
  • Shares traded0.00
  • 1 Year change+45.16%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 16:20 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company's product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.

  • Revenue in GBP (TTM)36.80m
  • Net income in GBP9.50m
  • Incorporated2006
  • Employees85.00
  • Location
    Niox Group PLCHayakawa BuildingThe Oxford Science ParkOXFORD OX4 4GBUnited KingdomGBR
  • Phone+44 186 540 5560
  • Fax+44 186 578 4576
  • Websitehttps://investors.niox.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.